Table III.
Association between NANOG expression and the clinical and pathological characteristics of patients with epithelial ovarian cancer.
| NANOG expression | |||||
|---|---|---|---|---|---|
| Parameter | n | Positive | Negative | χ2 | P-value |
| Age, years | 0.440 | 0.507 | |||
| <50 | 20 | 13 | 7 | ||
| ≥50 | 41 | 23 | 18 | ||
| Tissue type | 1.841 | 0.606 | |||
| Serous | 38 | 24 | 14 | ||
| Mucinous | 10 | 4 | 6 | ||
| Endometrioid | 10 | 6 | 4 | ||
| Other | 3 | 2 | 1 | ||
| Stage | 12.273 | <0.001 | |||
| I–II | 21 | 6 | 15 | ||
| III–IV | 40 | 30 | 10 | ||
| Histological grade | 3.457 | 0.063 | |||
| G1 | 21 | 9 | 12 | ||
| G2-G3 | 40 | 27 | 13 | ||
| Lymph node metastasis | 1.699 | 0.192 | |||
| Yes | 23 | 16 | 7 | ||
| No | 38 | 20 | 18 | ||
| Platinum sensitivity | 5.307 | 0.021 | |||
| Resistant | 17 | 14 | 3 | ||
| Sensitive | 44 | 22 | 22 | ||
NANOG expression is associated with disease staging (χ2=12.273, P<0.001) and platinum resistance (χ2=5.307, P=0.021) in patients with EOC. EOC, epithelial ovarian cancer; NANOG, homeobox protein NANOG.